Some mechanisms of Lactobacillus reuteri action as a probiotic microorganism

Simple item page
dc.citation.epage132
dc.citation.issue1
dc.citation.spage127
dc.contributor.affiliationНаціональний університет “Львівська політехніка”
dc.contributor.affiliationLviv Polytechnic National University
dc.contributor.authorЧервецова, В. Г.
dc.contributor.authorДмитрів, А. З.
dc.contributor.authorГавриляк, В. В.
dc.contributor.authorЛубенець, В. І.
dc.contributor.authorChervetsova, V. H.
dc.contributor.authorDmytriv, A. Z.
dc.contributor.authorHavryliak, V. V.
dc.contributor.authorLubenets, V. I.
dc.coverage.placenameLviv
dc.coverage.placenameLviv
dc.date.accessioned2024-01-22T09:22:47Z
dc.date.available2024-01-22T09:22:47Z
dc.date.created2020-02-21
dc.date.issued2020-02-21
dc.description.abstractУ роботі розглянуто окремі морфологічні, фізіологічні та біохімічні характеристики пробіотичного виду молочнокислих бактерій Lactobacillus reuteri. Цей вид, відповідно до літературних джерел, виділено з нормальної мікробіоти людини, інших представників класу Mammalia, а також бройлерів та хлібної закваски. Опрацювання літературних та інтернет-джерел дало змогу визначити важливість застосування різних штамів L. reuteri у сучасних біологічно активних харчових добавках. У роботі розглянуто деякі фізіологічні особливості цього мікроорганізму з погляду позитивного впливу на функціонування шлунково-кишкового тракту людини та формування імунітету. На основі розглянутих теоретичних даних зроблено висновок про необхідність подальшого практичного вивчення L. reuteri як потенційного пробіотика для фармацевтичної та харчової промисловості.
dc.description.abstractSome morphological, physiological and biochemical characteristics of the probiotic species of lactic acid bacteria Lactobacillus reuteri are presented in the work. This species, according to literature sources, were isolated from the normal human microbiota, other members of the class Mammalia, as well as broilers and sourdough. The study of literature and Internet sources identified the importance of using different strains of L. reuteri in modern dietary supplements.Some physiological features of this microorganism in terms of positive effects on the functioning of the human gastrointestinal tract and the formation of immunity were considered. According to processed datait is concluded that there is a necessity for further practical study of L. reuteri as a potential probiotic for the pharmaceutical and food industries.
dc.format.extent127-132
dc.format.pages6
dc.identifier.citationSome mechanisms of Lactobacillus reuteri action as a probiotic microorganism / V. H. Chervetsova, A. Z. Dmytriv, V. V. Havryliak, V. I. Lubenets // Chemistry, Technology and Application of Substances. — Lviv : Lviv Politechnic Publishing House, 2022. — Vol 5. — No 1. — P. 127–132.
dc.identifier.citationenSome mechanisms of Lactobacillus reuteri action as a probiotic microorganism / V. H. Chervetsova, A. Z. Dmytriv, V. V. Havryliak, V. I. Lubenets // Chemistry, Technology and Application of Substances. — Lviv : Lviv Politechnic Publishing House, 2022. — Vol 5. — No 1. — P. 127–132.
dc.identifier.doidoi.org/10.23939/ctas2022.01.127
dc.identifier.urihttps://ena.lpnu.ua/handle/ntb/60921
dc.language.isoen
dc.publisherLviv Politechnic Publishing House
dc.relation.ispartofChemistry, Technology and Application of Substances, 1 (5), 2022
dc.relation.references1. Hou, C., Zeng, X., Yang, F. et all. (2015). Study and use of the probiotic Lactobacillus reuteri in pigs: a review. Journal of animal science and biotechnology, 6, 156–160.
dc.relation.references2. Sung, V., Hiscock, H., Tang, M. et all. (2014) Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. An J Physiol Gastrointest Liver Physiol., H988–H994.
dc.relation.references3. Mu, Q., Tavella, V., Luo, X. (2018). Role of Lactobscillus reuteri in human health and diseases. Frontiers in Microbiology, 9, 124–130/
dc.relation.references4. Liu, Y., Fatheree, N., Mangalat, N., Rhoads, J. (2010). Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. An J. Physiol Gastrointest Liver Physiol., G1087–G1096.
dc.relation.references5. Thomas, C., Hong, T., J. van Pijkeren et all. (2012). Histamine Derived from Probiotic Lactobacillus reuteri Suppresses TNF via Modulation of PKA and ERK Signaling. PLoS ONE, 244–230.
dc.relation.references6. Iyer, C., Kosters, A., Sethi, G. et all. (2008). Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kB and MAPK signalling. Cellular Microbiology, 10, 1442–1452.
dc.relation.references7. Sung, V., D’Amico, F., Cabana, M. (2018). Lactobacillus reuteri to Treat Infant Colic: A Metaanalysis. Pediatrics, No. 2, 233–238.
dc.relation.references8. Versalovic, J., Jones, S. (2009). Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiology, 1012–1017.
dc.relation.references9. Mukai, T., Asasaka, T., Sato, E. et all. (2002). Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunology and Medical Microbiology, 32, 105–110.
dc.relation.references10. Taranto, M., Vera, J., Hugenholtz, J. et all. (2003). Lactobacillus reuteri CRL1098 Produces Cobalamin. American Society for Microbiology, 5643–5647.
dc.relation.references11. Gänzle, M., Höltzel, A., Walter, J. et all. (2000). Characterization of Reutericyclin Produced by Lactobacillus reuteri LTH2584. Applied and environmental microbiology, 4325–4333.
dc.relation.references12. Valeur, N., Engel, P., Carbajal, N. et all. (2004). Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract. Applied and Environmental Microbiology, 1176–1181.
dc.relation.references13. Forsythe, P., Inman, M., Bienenstock, J. (2006). Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. American Journal Of Respiratory And Critical Care Medicine, 561–569.
dc.relation.references14. Jones, M., Martoni, C., Parent, M., Prakash, S. (2012). Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. British Journal of Nutrition, 1505–1513.
dc.relation.references15. Sinkiewicz, G., Ljunggren, L. Occurrence of Lactobacillus reuteri in human breast milk (2009). Microbial Ecology in Health and Disease, 122–126.
dc.relation.references16. Axelsson, L., Chung, T., Dobrogosz, W., Lindgren, S. (1989). Production of a Broad Spectrum Antimicrobial Substance by Lactobacillus reuteri. Microbial Ecology in Health and Disease, 131–136.
dc.relation.references17. Axelsson, L., Chung, T., Dobrogosz, W., Lindgren, S. (1989). In Vitro Studies on Reuterin Synthesis by Lactobacillus reuteri. Microbial Ecology in Health and Disease, 137–144.
dc.relation.references18. Vicario, M., Santos, A., Violant, D. et all. (2013). Clinical changes in periodontal subjects with the probiotic Lactobacillus reuteri Prodentis: A preliminary randomized clinical trial. Acta Odontologica Scandinavica, 813–819.
dc.relation.references19. Jones, M., Martoni, C., Parent, M., Prakash, S. (1988). Production and Isolation of Reuterin, a Growth Inhibitor Produced by Lactobacillus reuteri. Antimicrobial Agents And Chemotherapy, 1854–1858.
dc.relation.references20. Talarico, T., Dobrogosz, W. (1989). Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrobial Agents And Chemotherapy, 674–679.
dc.relation.references21. Martin, H. Floch, Yehuda, Ringel and Walker, W. Allan (2017). The microbiota in gastrointestinal pathophysiology. B.: Academic Press, Ch. 8, 89–97.
dc.relation.references22. Chervetsova, V. H., Dmytriv, A. Z., Shved, O. V., Konechna, R. T., Lubenetsʹ, V. I. (2021). Analiz vykorystannya Lactobacillus reuteri yak probiotyka, 254–266. In: Traditional medicine and pharmacology. Achievements, innovation, and alternatives: collective monograph / Gryschenko, V., etc. International Science Group. Boston: Primedia eLaunch, 327 p. DOI: 10.46299/ISG.2021.MONO.MED.II.
dc.relation.referencesen1. Hou, C., Zeng, X., Yang, F. et all. (2015). Study and use of the probiotic Lactobacillus reuteri in pigs: a review. Journal of animal science and biotechnology, 6, 156–160.
dc.relation.referencesen2. Sung, V., Hiscock, H., Tang, M. et all. (2014) Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. An J Physiol Gastrointest Liver Physiol., H988–H994.
dc.relation.referencesen3. Mu, Q., Tavella, V., Luo, X. (2018). Role of Lactobscillus reuteri in human health and diseases. Frontiers in Microbiology, 9, 124–130/
dc.relation.referencesen4. Liu, Y., Fatheree, N., Mangalat, N., Rhoads, J. (2010). Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. An J. Physiol Gastrointest Liver Physiol., G1087–G1096.
dc.relation.referencesen5. Thomas, C., Hong, T., J. van Pijkeren et all. (2012). Histamine Derived from Probiotic Lactobacillus reuteri Suppresses TNF via Modulation of PKA and ERK Signaling. PLoS ONE, 244–230.
dc.relation.referencesen6. Iyer, C., Kosters, A., Sethi, G. et all. (2008). Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kB and MAPK signalling. Cellular Microbiology, 10, 1442–1452.
dc.relation.referencesen7. Sung, V., D’Amico, F., Cabana, M. (2018). Lactobacillus reuteri to Treat Infant Colic: A Metaanalysis. Pediatrics, No. 2, 233–238.
dc.relation.referencesen8. Versalovic, J., Jones, S. (2009). Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiology, 1012–1017.
dc.relation.referencesen9. Mukai, T., Asasaka, T., Sato, E. et all. (2002). Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunology and Medical Microbiology, 32, 105–110.
dc.relation.referencesen10. Taranto, M., Vera, J., Hugenholtz, J. et all. (2003). Lactobacillus reuteri CRL1098 Produces Cobalamin. American Society for Microbiology, 5643–5647.
dc.relation.referencesen11. Gänzle, M., Höltzel, A., Walter, J. et all. (2000). Characterization of Reutericyclin Produced by Lactobacillus reuteri LTH2584. Applied and environmental microbiology, 4325–4333.
dc.relation.referencesen12. Valeur, N., Engel, P., Carbajal, N. et all. (2004). Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract. Applied and Environmental Microbiology, 1176–1181.
dc.relation.referencesen13. Forsythe, P., Inman, M., Bienenstock, J. (2006). Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. American Journal Of Respiratory And Critical Care Medicine, 561–569.
dc.relation.referencesen14. Jones, M., Martoni, C., Parent, M., Prakash, S. (2012). Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. British Journal of Nutrition, 1505–1513.
dc.relation.referencesen15. Sinkiewicz, G., Ljunggren, L. Occurrence of Lactobacillus reuteri in human breast milk (2009). Microbial Ecology in Health and Disease, 122–126.
dc.relation.referencesen16. Axelsson, L., Chung, T., Dobrogosz, W., Lindgren, S. (1989). Production of a Broad Spectrum Antimicrobial Substance by Lactobacillus reuteri. Microbial Ecology in Health and Disease, 131–136.
dc.relation.referencesen17. Axelsson, L., Chung, T., Dobrogosz, W., Lindgren, S. (1989). In Vitro Studies on Reuterin Synthesis by Lactobacillus reuteri. Microbial Ecology in Health and Disease, 137–144.
dc.relation.referencesen18. Vicario, M., Santos, A., Violant, D. et all. (2013). Clinical changes in periodontal subjects with the probiotic Lactobacillus reuteri Prodentis: A preliminary randomized clinical trial. Acta Odontologica Scandinavica, 813–819.
dc.relation.referencesen19. Jones, M., Martoni, C., Parent, M., Prakash, S. (1988). Production and Isolation of Reuterin, a Growth Inhibitor Produced by Lactobacillus reuteri. Antimicrobial Agents And Chemotherapy, 1854–1858.
dc.relation.referencesen20. Talarico, T., Dobrogosz, W. (1989). Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrobial Agents And Chemotherapy, 674–679.
dc.relation.referencesen21. Martin, H. Floch, Yehuda, Ringel and Walker, W. Allan (2017). The microbiota in gastrointestinal pathophysiology. B., Academic Press, Ch. 8, 89–97.
dc.relation.referencesen22. Chervetsova, V. H., Dmytriv, A. Z., Shved, O. V., Konechna, R. T., Lubenetsʹ, V. I. (2021). Analiz vykorystannya Lactobacillus reuteri yak probiotyka, 254–266. In: Traditional medicine and pharmacology. Achievements, innovation, and alternatives: collective monograph, Gryschenko, V., etc. International Science Group. Boston: Primedia eLaunch, 327 p. DOI: 10.46299/ISG.2021.MONO.MED.II.
dc.rights.holder© Національний університет “Львівська політехніка”, 2022
dc.subjectпробіотики
dc.subjectмолочнокислі бактерії
dc.subjectLactobacillus reuteri
dc.subjectдисбактеріоз
dc.subjectлікарські препарати
dc.subjectprobiotics
dc.subjectlactic acid bacteria
dc.subjectLactobacillus reuteri
dc.subjectdysbacteriosis
dc.subjectdrugs
dc.titleSome mechanisms of Lactobacillus reuteri action as a probiotic microorganism
dc.title.alternativeДеякі механізми дії Lactobacillus reuteri як пробіотичного мікроорганізму
dc.typeArticle

Files

Original bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
2022v5n1_Chervetsova_V_H-Some_mechanisms_of_127-132.pdf
Size:
329.54 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
2022v5n1_Chervetsova_V_H-Some_mechanisms_of_127-132__COVER.png
Size:
480.79 KB
Format:
Portable Network Graphics
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.89 KB
Format:
Plain Text
Description:
Download

Collections

Chemistry, Technology and Application of Substances. – 2022. – Vol. 5, No. 1